Summary
Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know
Genelux Corporation (GNLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point
Topline results from phase 3 OnPrime/GOG-3076 study using Olvi-Vec for the treatment of patients with platinum-resistant recurrent ovarian cancer, are expected in the 2nd half of 2025. Interim data from phase 2 U.S. trial using Olvi-Vec for the treatment of patients with non-small cell lung cancer is expected mid-2025. Interim results from phase 1b/2 China study, using Olvi-Vec for the treatment of patients with small-cell lung cancer, are expected 2nd half of 2024.
Genelux Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| YA Yinka Akinsola Blue Trust Inc. | 9,479 | $124,634.38 | $26,967.75 | -$97,666.63 | -78.36% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 21,824 | $52,814 | $62,962.24 | $10,148.24 | 19.22% |
 Michael Byun SageView Advisory Group LLC | 1,264 | $5,512 | $3,570.8 | -$1,941.2 | -35.22% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 3 | $7 | $8.49 | $1.49 | 21.29% |
| CCW Cassaday & Co. Wealth Management LLC Cassaday & Co. Wealth Management LLC | 2,553 | $6,179 | $7,224.99 | $1,045.99 | 16.93% |
Genelux Corp. (GNLX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Genelux Corp. ever had a stock split?
Genelux Corp. Profile
| Biotechnology Industry | Healthcare Sector | Thomas D. Zindrick CEO | NASDAQ (CM) Exchange | 36870H103 CUSIP |
| US Country | 26 Employees | - Last Dividend | - Last Split | 26 Jan 2023 IPO Date |
Overview
Genelux Corporation, established in 2001 and based in Westlake Village, California, is at the forefront of the clinical-stage biopharmaceutical industry, specializing in the development of innovative oncolytic viral immunotherapies. These therapies are aimed at providing new treatment options for patients battling aggressive and/or difficult-to-treat solid tumor types. Through groundbreaking research and development, Genelux Corporation seeks to leverage the potential of viral vectors for cancer therapy, highlighting its commitment to addressing unmet medical needs in oncology.
Products and Services
- Olvi-Vec
- V2ACT Immunotherapy
- V-VET1
As the lead product candidate of Genelux Corporation, Olvi-Vec represents a significant advancement in oncolytic viral therapy. This proprietary modified strain of the vaccinia virus is being developed for the treatment of ovarian cancer and non-small cell lung cancer. By targeting these complex and challenging forms of cancer, Olvi-Vec exemplifies the company's innovative approach to oncology, striving to provide patients with more effective and targeted treatment options.
In the pipeline of Genelux Corporation's cancer treatment solutions, V2ACT Immunotherapy stands out as a promising new approach to combating pancreatic cancer. This innovative therapy is designed to harness the body's immune response, aiming to fight cancer more effectively and with potentially fewer side effects than traditional treatments. By focusing on pancreatic cancer, Genelux is addressing one of the most deadly and difficult-to-treat cancer types.
Expanding its impact beyond human health, Genelux Corporation has entered into a licensing agreement with ELIAS Animal Health, LLC for V-VET1. This clinical-stage animal health product candidate showcases Genelux's commitment to leveraging its viral therapy platform for the benefit of veterinary medicine as well. V-VET1 represents a significant step forward in the treatment of diseases in animals, highlighting the company's dedication to improving health across species.
